Quetiapine in the treatment of psychosis in Parkinson's disease (Q24628941)

Therapeutic advances in neurological disorders

Europe PubMed Central

title

Quetiapine in the treatment of psychosis in Parkinson's disease (English)

0 references

1 reference

1 reference

Paul Shotbolt

1

0 references

author name string

Mike Samuel

series ordinal

2

0 references

Anthony David

series ordinal

3

0 references

language of work or name

English

0 references

publication date

November 2010

0 references

published in

1 reference

Dopamine agonist therapy in early Parkinson's disease

volume

3

0 references

issue

6

0 references

page(s)

339-50

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Epidemiology of psychosis in Parkinson's disease.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Extrapyramidal side-effects of antipsychotics in a randomised trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Rivastigmine for dementia associated with Parkinson's disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Management of psychosis in Parkinson's disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Efficacy of quetiapine in Parkinson's patients with psychosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

19 June 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Reality monitoring and visual hallucinations in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Risperidone and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

A semi-structured interview to assess visual hallucinations in older people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610389656

Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002640

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

28 November 2018

1 reference

12 December 2020

Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis

1 reference

12 December 2020

1 reference

12 December 2020

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756285610389656

1 reference

562751

562751

1 reference

1 reference

1 reference